Brendan joined White & Case in 2017 as an associate in the Intellectual Property Group. His practice focuses on a variety of intellectual property issues, including worldwide patent portfolio development, patent prosecution, due diligence, and litigation support. Brendan has extensive experience providing freedom-to-operate, invalidity and patentability opinions, and he also assists the patent litigation group in contested proceedings, such as inter partes review and post grant review proceedings.
Brendan regularly works with clients and inventors from large corporations, start-up companies and universities to develop ideal intellectual property protection strategies of technologies such as enzyme replacement therapies, modified polypeptides, fusion proteins, small molecules, nucleic acid therapeutics (including CRISPR and RNAi), antibody development, methods of treatment, diagnostic methods, drug formulations, and dosage regimens.
Brendan has experience in drafting and assessing intellectual property provisions of assignments, license, material transfer, acquisition, and research agreements and public offering documents. His practice also involves evaluating the intellectual property portfolios of target companies or potentially blocking third-parties. Upon identification of any intellectual property issues, Brendan assists clients in identifying appropriate mitigation strategies.
Prior to joining White & Case, Brendan was a technical advisor and later a patent attorney at an international law firm. Brendan's doctoral research focused on prion pathogenesis and neuronal signaling in the eye.
Represents a pharmaceutical company in the worldwide prosecution of its clinical candidates. This includes the development of a patent portfolio for several different polypeptide ligand traps, as well as methods of using those compounds to treat various diseases.
Represents a pharmaceutical company in defending several of its patents in inter partes review and post grant review proceedings.
Represented a biotechnology company in the worldwide prosecution of a multi-billion dollar antibody therapeutic. This included assisting the litigation team to design strategies to preserve granted patents in post-grant proceedings.*
Provided IP due diligence support to a pharmaceutical company in connection with an exclusive licensing arrangement worth in excess of USD $400 million with a company developing messenger RNA therapeutics.*
Provided strategic guidance to an agricultural industry leader in a contractual and patent validity dispute involving one of the client's key herbicide products.*
Provided IP due diligence support to a biotechnology company in connection with an investment agreement worth in excess of USD $300 million for CRISPR-based technology.*
*Matters prior to joining White & Case.